Tanuja Nesari

Prof. Dr. Tanuja Nesari


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2022 in Frontiers in Public Health
Verified
Journal Article
Open access
TNTanuja Nesari
Tanuja Nesari
SKSujata Kadam
Sujata Kadam
MVMahesh Vyas
Mahesh Vyas
VHVitthal G. Huddar
Vitthal G. Huddar
PPPradeep Kumar Prajapati
Pradeep Kumar Prajapati
RTRicha Tripathi
Richa Tripathi
Objective: The world continues to face the COVID-19 crisis, and efforts are underway to integrate traditional medicine interventions for its effective management. The study aimed to determine the efficacy of the “AYURAKSHA” kit in terms of post-interventional percentage of COVID-19 IgG positivity, immunity levels, and quality of life (QoL) against COVID-19.Method: This was a non-randomized controlled, prospective intervention trial, done after the distribution of 80,000 AYURAKSHA kits (constituent of Sanshamani Vati, AYUSH Kadha, and Anu Taila) among Delhi police participants in India. Among 47,827 participants, the trial group (n = 101) was evaluated with the positivity percentage of IgG COVID-19 and Immune Status Questionnaire (ISQ) scores as a primary outcome and the WHO Quality of Life Brief Version (QOL BREF) scores along with hematological parameters as a secondary outcome in comparison to the control group (n = 71).Results: The data showed that the percentage of COVID-19 IgG positivity was significantly lower in the trial group (17.5 %) as compared to the control group (39.4 %, p = 0.003), indicating the lower risk (55.6%) of COVID-19 infection in the trial group. The decreased incidence (5.05%) and reduced mortality percentage (0.44%) of COVID-19 among Delhi police officers during peak times of the pandemic also corroborate our findings. The ISQ score and WHO-QOL BREF tool analysis showed the improved scores in the trial group when compared with the controls. Furthermore, no dysregulated blood profile and no increase in inflammation markers like C-reactive protein, erythrocyte sedimentation rate, Interleukin-6 (IL-6) were observed in the trial group. However, significantly enhanced (p = 0.027) IL-6 levels and random blood sugar levels were found in the control group (p = 0.032), compared to a trial group (p = 0.165) post-intervention. Importantly, the control group showed more significant (p = 0.0001) decline in lymphocyte subsets CD3+ (% change = 21.04), CD4+ (% change = 20.34) and CD8+ (% change = 21.54) levels than in trial group, confirming more severity of COVID-19 infection in the control group.Conclusion: The AYURAKSHA kit is associated with reduced COVID-19 positivity and with a better quality of life among the trial group. Hence, the study encourages in-depth research and future integration of traditional medicines for the prevention of the COVID-19 pandemic.Clinical trial registration: http://ctri.nic.in/, identifier: CTRI/2020/05/025171.

1 April 2023 in International Journal of Ayurveda Research
Verified
Journal Article
Open access
TNTanuja Nesari
Tanuja Nesari

15 August 2023 in Complementary Therapies in Medicine
Verified
Journal Article
Open access
BPBhushan Patwardhan
Bhushan Patwardhan
LWL. Susan Wieland
L. Susan Wieland
OAObijiofor Aginam
Obijiofor Aginam
ACAnchalee Chuthaputti
Anchalee Chuthaputti
RGRicardo Ghelman
Ricardo Ghelman
RARabinarayan Acharya
Rabinarayan Acharya

11 October 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
HSHeena Saini
Heena Saini
PGPrashant Kumar Gupta
Prashant Kumar Gupta
AMArun Kumar Mahapatra
Arun Kumar Mahapatra
SRShrikrishna Rajagopala
Shrikrishna Rajagopala
RTRicha Tripathi
Richa Tripathi
TNTanuja Nesari
Tanuja Nesari
Breast Cancer (BC) is the most common cause of cancer-associated deaths in females worldwide. Despite advancements in BC treatment driven by extensive characterization of its molecular hallmarks, challenges such as drug resistance, tumor relapse, and metastasis persist. Therefore, there is an urgent need for alternative treatment approaches with multi-modal efficacy to overcome these hurdles. In this context, natural bioactives are increasingly recognized for their pivotal role as anti-cancer compounds. This study focuses on predicting molecular targets for key herbal phytoconstituents—gallic acid, piperine, quercetin, resveratrol, and beta-sitosterol—present in the polyherbal formulation, Krishnadi Churna. Using an in-silico network pharmacology model, key genes were identified and docked against these marker compounds and controls. Mammary carcinoma emerged as the most significant phenotype of the putative targets. Analysis of an online database revealed that out of 135 predicted targets, 134 were mutated in breast cancer patients. Notably, ESR1, CYP19A1, and EGFR were identified as key genes which are known to regulate the BC progression. Docking studies demonstrated that the herbal phytoconstituents had similar or better docking scores than positive controls for these key genes, with convincing protein-ligand interactions confirmed by molecular dynamics simulations, MM/GBSA and free energy landscape (FEL) analysis. Overall, this study highlights the predictive potential of herbal phytoconstituents in targeting BC genes, suggesting their promise as a basis for developing new therapeutic formulations for BC.

1 January 2024 in American Journal of Translational Research
Verified
Journal Article
Closed access
HSHeena Saini
Heena Saini
PBPartha Basu
Partha Basu
TNTanuja Nesari
Tanuja Nesari
VHVitthal Govindappa Huddar
Vitthal Govindappa Huddar
KRKoninika Ray
Koninika Ray
RTRicha Tripathi
Richa Tripathi
Breast cancer (BC) ranks number one among cancers affecting women globally. Serious concerns include delayed diagnosis, poor prognosis, and adverse side effects of conventional treatment, leading to residual morbidity. Therefore, an alternative treatment approach that is safe and effective has become the need of the hour. In this regard, plant-based medicines via a combination of conventional drugs are gaining increasing acceptance worldwide, playing a pivotal role in cancer management as proven by their efficacy evaluation studies. This review aims to fill the knowledge gaps by providing the preclinical evidence of cellular and molecular mechanisms of Indian phytomedicines in targeting varied pathways of breast cancer progression. A comprehensive search was performed on different platforms, followed by screening of relevant studies for review. In this article, the in-depth of various botanical drugs covering their nomenclature, dosage, toxicity, and modus operandi in BC cells have been extensively discussed. Various signaling pathways like Notch signaling, MAPK signaling, apoptosis, Wnt signaling, etc. regulated by herbal medicine treatment in BC are also highlighted to understand the drug mechanism better. This will guide the researchers to plan future strategies and generate more robust integrated evidence of plant-based drugs or botanical formulations for their potential role in the management of BC.

1 April 2023 in Journal of Ayurveda Case Reports
Verified
Journal Article
Open access
TNTanuja Nesari
Tanuja Nesari